SCHEMBL25802138

SCHEMBL25802138

CCOP(C)(=O)C(Cc1nc(-c2ccc(C)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.48
MAPK1 P28482 3/20 0.48
MAPT P10636 7/20 0.45
NPSR1 Q6W5P4 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 5/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PSMB5 P28074 1/20 0.43
HPGD P15428 3/20 0.42
ALDH1A1 P00352 2/20 0.42
ATM Q13315 1/20 0.42
HTT P42858 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25802131 0.91 LMNA (0.39) LMNAMAPK1MAPTSMN1; SMN2TSHR
SCHEMBL25801755 0.91 HTT (0.48) LMNAMAPK1MAPTNPSR1SMN1; SMN2
SCHEMBL25802128 0.91 LMNA (0.39) LMNAMAPK1MAPTSMN1; SMN2TDP1
SCHEMBL25801976 0.88 CYP1A2 (0.39) LMNAMAPK1MAPTSMN1; SMN2TSHR
SCHEMBL25801943 0.88 ACACB (0.45) LMNAMAPTNPSR1SMN1; SMN2TSHR
SCHEMBL25801780 0.88 SPHK1 (0.43) LMNAMAPTNPSR1SMN1; SMN2TSHR
SCHEMBL25801802 0.87 SPHK1 (0.46)
SCHEMBL25802076 0.86 RAB9A (0.38) LMNAMAPK1MAPTSMN1; SMN2TSHR
SCHEMBL25801981 0.86 S1PR4 (0.39) LMNAMAPK1NPSR1SMN1; SMN2TSHR
SCHEMBL25801989 0.86 SPHK1 (0.40) LMNAMAPK1NPSR1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 LMNA 3388/4885MAPK1 3947/4885MAPT 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.